This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2019 Mar 16;393(10176):1078-1080.

doi: 10.1016/S0140-6736(19)30416-7. Epub 2019 Feb 23.

Technology to overcome clinical inertia in insulin therapy

Mark L Evans¹, Rajna Golubic²

Affiliations

Affiliations

¹ Wellcome Trust, MRC Institute of Metabolic Science and Department of Medicine, University of Cambridge, Cambridge NIHR Biomedical Campus, Cambridge CB20QQ, UK. Electronic address: mle24@cam.ac.uk.
² Wellcome Trust, MRC Institute of Metabolic Science and Department of Medicine, University of Cambridge, Cambridge NIHR Biomedical Campus, Cambridge CB20QQ, UK.

PMID: 30808513
DOI: 10.1016/S0140-6736(19)30416-7

Technology to overcome clinical inertia in insulin therapy

Mark L Evans et al. Lancet. 2019.

. 2019 Mar 16;393(10176):1078-1080.

doi: 10.1016/S0140-6736(19)30416-7. Epub 2019 Feb 23.

Authors

Mark L Evans¹, Rajna Golubic²

Affiliations

¹ Wellcome Trust, MRC Institute of Metabolic Science and Department of Medicine, University of Cambridge, Cambridge NIHR Biomedical Campus, Cambridge CB20QQ, UK. Electronic address: mle24@cam.ac.uk.
² Wellcome Trust, MRC Institute of Metabolic Science and Department of Medicine, University of Cambridge, Cambridge NIHR Biomedical Campus, Cambridge CB20QQ, UK.

PMID: 30808513
DOI: 10.1016/S0140-6736(19)30416-7

No abstract available

PubMed Disclaimer

Similar articles

Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy.
Shubrook JH. Shubrook JH. J Fam Pract. 2018 Aug;67(8 suppl):S49-S54. J Fam Pract. 2018. PMID: 30137054 No abstract available.
Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.
Charbonnel PB. Charbonnel PB. Diabetes Metab. 2015 Dec;41(6 Suppl 1):6S1-6S2. doi: 10.1016/S1262-3636(16)30001-5. Diabetes Metab. 2015. PMID: 26774014 No abstract available.
Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
Kalra S, Kalhan A, Berard L. Kalra S, et al. Postgrad Med. 2020 Nov;132(8):663-666. doi: 10.1080/00325481.2020.1809906. Epub 2020 Oct 19. Postgrad Med. 2020. PMID: 32781867 No abstract available.
Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.
Gómez-Huelgas R, Azriel S, Puig-Domingo M, Vidal J, de Pablos-Velasco P. Gómez-Huelgas R, et al. Int J Clin Pharmacol Ther. 2015 Mar;53(3):230-40. doi: 10.5414/CP202052. Int J Clin Pharmacol Ther. 2015. PMID: 25066229 Review.
Early insulin treatment in type 2 diabetes: what are the pros?
Meneghini LF. Meneghini LF. Diabetes Care. 2009 Nov;32 Suppl 2(Suppl 2):S266-9. doi: 10.2337/dc09-S320. Diabetes Care. 2009. PMID: 19875562 Free PMC article. Review. No abstract available.

See all similar articles

Cited by

Outcomes of a feasibility trial using an innovative mobile health programme to assist in insulin dose adjustment.
Menon A, Fatehi F, Ding H, Bird D, Karunanithi M, Gray L, Russell A. Menon A, et al. BMJ Health Care Inform. 2019 Oct;26(1):e100068. doi: 10.1136/bmjhci-2019-100068. BMJ Health Care Inform. 2019. PMID: 31676495 Free PMC article.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information